Sawai Group Holdings Co (4887) Corporate presentation summary

Review of previous medium-term plan (START 2024)

• Increased Japanese generics market share to 17.1% and production capacity to 18.5 billion tablets, while withdrawing from the U.S. business due to low returns.

• Launched 65 new products over three years, leveraging patent strategy and formulation technology.

• Invested 58.5 billion yen in production facilities, aiming for 20 billion tablets annual capacity.

• Initiated new businesses in digital medical devices, health foods, and orphan drugs.

• Maintained consistent dividends and strategic R&D investments, with 17 billion yen in dividends over three years.

Vision for 2030

• Aims to be a leading healthcare provider, expanding access and offering a mix of generics, digital devices, and health foods.

• Targets 310 billion yen in revenue and 13%+ ROE by FY2030, with 25% generics market share and 25 billion tablets production capacity.

• Focuses on disease prevention, diagnosis, and treatment, with sustainability and talent development as core pillars.

• Responds to Japan’s aging society and rising medical costs by emphasizing prevention and technological innovation.

Medium-term business plan "Beyond 2027"

• Prioritizes establishing a trusted corporate foundation, with enhanced compliance and quality assurance systems.

• Plans to launch over 44 new products in three years and expand in-house production to 25 billion tablets by FY2030.

• Invests in digital medical devices, health foods, and orphan drugs, with new product launches and overseas expansion.

• Strengthens talent acquisition, diversity, and flexible work styles to support sustainable growth.

• Commits to 46% CO2 emissions reduction by 2030 and net zero by 2050, with increased recycling and energy efficiency.